Acute Bronchitis Clinical Trial
Official title:
Evaluation of Effectiveness of the Sublimated Mare Milk Supplement in Protection of Gut Mucosal Lining During Antibiotic Treatment
This clinical trial studies the effect of sublimated mare milk supplement on gut microbiome of patients with acute bronchitis.
Food has a significant effect on the health of the body, the relationship between diet and health actualizes the importance of expanding the research of functional products. In mare's milk contains about 40 biological components necessary for the human body: amino acids, fats, enzymes (lysozyme, amylase), microelements (calcium, sodium, potassium, phosphorus, iron, magnesium, copper, iodine, sulfur, cobalt, zinc, bromine) and vitamins (A, C, B1, B2, B6, B12, E, H, PP, beta-carotene, folic acid) in optimally balanced proportions. A high percentage of nutrients, including vitamins, amino acids, contribute to immunomodulation, increasing the adaptogenic properties of the body. Valiev A demonstrated the effect of the essential fatty acids of mare's milk on immunocompetent cells and non-specific resistance after 6 weeks from the beginning of inclusion in the ration of mare's milk. Secretory IgA is the main immunoglobulin of mare's milk. The homology of human secretory IgA and mare's was previously demonstrated by cross-reactions using human anti-IgA antiserum. The mare's milk has a powerful detoxification effect, the mare's microflora neutralizes the effect of mutagens, possesses, replenishes with the necessary complex of nutrients and removes toxins from the body. The milk has a certain degree of antimicrobial effect in relation to opportunistic and pathogenic fungi, bacteria and viruses due to its own microflora. The mare's milk is rich in active substances, natural enzymes that help regulate intestinal flora, limiting the growth of unwanted bacteria and increasing the growth of bifidobacteria and lactic acid bacteria. In addition, the composition of mare's milk provided immunoglobulins A, M and G, which act as a marker of those microorganisms that can be pathogenic, which facilitates the protection task. The high antimicrobial activity of mare's milk is associated with the lysozyme contained in it, immunoglobulins, lactoperoxidase and lactoferrin. Getting into the digestive tract lysozyme has a powerful normalizing effect on the composition of the microbial flora of the mouth and intestines. Lysozyme of breast milk is 100 times more active than lysozyme of cow's milk. It not only inhibits the growth of pathogenic flora, but also promotes the growth of bifidoflora in the intestines of infants. In the framework of the project, methods for the restoration of the mucos layer of the intestine after antibiotic therapy will be developed. In order to develop the algorithm, preliminary studies will be made of changes in the structure of the intestinal microbiota after antibiotic therapy. Recruiting of patients with infectious / non-infectious pathology is supposed, clinical and laboratory examination, biomaterial sampling during antibiotic therapy, 1-5 days and 1-60 days after completion will be performed. Along with the study of microflora, local immunity studies will be carried out. To study the fundamental foundations, experimental studies will be carried out on laboratory animals. On the basis of the knowledge obtained, an algorithm for the restoration of the mucinous layer of the intestine after antibiotic therapy will be published in the form of methodological recommendations. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03711292 -
Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings
|
N/A | |
Not yet recruiting |
NCT03517215 -
The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program
|
N/A | |
Completed |
NCT01420445 -
Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis
|
Phase 2 | |
Completed |
NCT00360464 -
A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases
|
Phase 3 | |
Completed |
NCT05344638 -
A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis
|
Phase 3 | |
Completed |
NCT06457269 -
Evaluating the Potential of Large Language Models for Respiratory Disease Consultations
|
N/A | |
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Recruiting |
NCT03827590 -
Clinical Trials to Assess the Efficacy and Safety of HLIM
|
Phase 3 | |
Completed |
NCT02792946 -
Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis
|
Phase 3 | |
Completed |
NCT01875757 -
Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life
|
Phase 3 | |
Recruiting |
NCT04252963 -
Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)
|
Phase 4 | |
Recruiting |
NCT06411925 -
The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients
|
Phase 4 | |
Completed |
NCT01416480 -
Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher
|
Phase 3 | |
Enrolling by invitation |
NCT05916768 -
Management of Acute Bronchitis With Pelargonium Sidoides Extract
|
N/A | |
Completed |
NCT03309800 -
A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients
|
Phase 2 | |
Completed |
NCT02250027 -
A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)
|
Phase 2 | |
Not yet recruiting |
NCT03310385 -
Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis
|
Phase 2 | |
Completed |
NCT03654196 -
A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients
|
Phase 3 | |
Completed |
NCT03011515 -
Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
|
||
Completed |
NCT02045394 -
Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study
|
N/A |